Vivus Adds $45.8M Ahead of Planned Qnexa Resubmission
By Jennifer Boggs
Wednesday, August 24, 2011
Mountain View, Calif.-based Vivus Inc. priced a registered direct offering of 6.9 million shares at $6.65 each for gross proceeds of $45.8 million to boost its balance sheet and support ongoing work with obesity drug Qnexa (phentermine/topiramate), including the resubmission of a new drug application (NDA) expected next quarter.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.